Maria Isabel Garcia Sanchez

Dr. Maria Isabel Garcia Sanchez

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LVLuisa Maria Villar
Luisa Maria Villar
BCBonaventura Casanova
Bonaventura Casanova
NONadia Ouamara
Nadia Ouamara
Manuel ComabellaManuel Comabella
Manuel Comabella
FJFarzaneh Jalili
Farzaneh Jalili
ABAmit Bar-Or
Amit Bar-Or

7 January 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LVLuisa Maria Villar
Luisa Maria Villar
LCLucienne Costa‐Frossard
Lucienne Costa‐Frossard
TMThomas Masterman
Thomas Masterman
OFOscar Fernandez
Oscar Fernandez
XMXavier Montalban
Xavier Montalban
JÁJosé C. Álvarez‐Cermeño
José C. Álvarez‐Cermeño

7 July 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
FMFuencisla Matesanz
Fuencisla Matesanz
VPVictor Potenciano
Victor Potenciano
MFMaria Fedetz
Maria Fedetz
PRPriscila Ramos-Mozo
Priscila Ramos-Mozo
MAMaría del Mar Abad-Grau
María del Mar Abad-Grau
AAAntonio Alcina
Antonio Alcina
Several variants in strong linkage disequilibrium (LD) at the SP140 locus have been associated with multiple sclerosis (MS), Crohn's disease (CD) and chronic lymphocytic leukemia (CLL). To determine the causal polymorphism, we have integrated high-density data sets of expression quantitative trait loci (eQTL), using GEUVADIS RNA sequences and 1000 Genomes genotypes, with MS-risk variants of the high-density Immunochip array performed by the International Multiple Sclerosis Genetic Consortium (IMSGC). The variants most associated with MS were also correlated with a decreased expression of the full-length RNA isoform of SP140 and an increase of an isoform lacking exon 7. By exon splicing assay, we have demonstrated that the rs28445040 variant was the causal factor for skipping of exon 7. Western blots of peripheral blood mononuclear cells from MS patients showed a significant allele-dependent reduction of the SP140 protein expression. To confirm the association of this functional variant with MS and to compare it with the best-associated variant previously reported by GWAS (rs10201872), a case–control study including 4384 MS patients and 3197 controls was performed. Both variants, in strong LD (r2 = 0.93), were found similarly associated with MS [P-values, odds ratios: 1.9E-9, OR = 1.35 (1.22–1.49) and 4.9E-10, OR = 1.37 (1.24–1.51), respectively]. In conclusion, our data uncover the causal variant for the SP140 locus and the molecular mechanism associated with MS risk. In addition, this study and others previously reported strongly suggest that this functional variant may be shared with other immune-mediated diseases as CD and CLL.

1 February 2012 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
LVLuisa Maria Villar
Luisa Maria Villar
MSMaria Isabel Garcia Sanchez
Maria Isabel Garcia Sanchez
LCLucienne Costa-Frossard
Lucienne Costa-Frossard
MEMercedes Espiño
Mercedes Espiño
ERErnesto Roldán
Ernesto Roldán
JÁJosé C. Álvarez-Cermeño
José C. Álvarez-Cermeño
Quiz Ref ID Multiple sclerosis (MS) is the most frequent chronic demyelinating disease of the central nervous system and a major cause of disability in young adults. It is considered to be an autoimmune disease in which activated lymphocytes enter the central nervous system and trigger an inflammatory cascade that leads to recruitment of other immune cells. This results in demyelination and axonal loss that leads to irreversible neurological deficits. Treatment with interferon beta or glatiramer acetate, the first disease-modifying therapies used to treat MS, improve the natural history of the disease and delay the onset of permanent neurological deficits.1 Nevertheless, their beneficial effect is partial because they only reduce the relapse rate by about 30%, and their effect on disability progression is more controversial. Quiz Ref ID Natalizumab is a humanized monoclonal antibody directed against the α4 chain of the adhesion molecule VLA-4. It was approved by the US Food and Drug Administration for the treatment of relapsing-remitting MS in 2004. It decreases the relapse rate by up to 68% and the rate of progression of disability by 42%, reducing magnetic resonance imaging (MRI) activity by up to 92%.2 Post hoc analyses of the pivotal trial (ie, the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis study [AFFIRM]) showed that the proportion of patients with no new or enlarging MRI-detected lesions during the study period was greater in the natalizumab group than in the placebo group.3 Therefore, disease remission seems an attainable goal for patients with MS who are treated with this new agent, something that the other disease-modifying therapies could not achieve in many cases.4

1 January 2019 in Autoimmunity Reviews
Verified
Journal Article
Closed access
PVPaloma Menendez Valladares
Paloma Menendez Valladares
MSMaria Isabel Garcia Sanchez
Maria Isabel Garcia Sanchez
MMMyriam Adorna Martínez
Myriam Adorna Martínez
JHJosé-Ángel Hernández-Rivas
José-Ángel Hernández-Rivas
CGCarmen Bermudo Guitarte
Carmen Bermudo Guitarte
GAGuillermo Izquierdo Ayuso
Guillermo Izquierdo Ayuso

1 November 2000 in JBIC Journal of Biological Inorganic Chemistry
Verified
Journal Article
Closed access
PDF file
MSMaria Isabel Garcia Sanchez
Maria Isabel Garcia Sanchez
Antonio Jesús Díaz-QuintanaAntonio Jesús Díaz-Quintana
Antonio Jesús Díaz-Quintana
Cecilia GotorCecilia Gotor
Cecilia Gotor
Jean-Pierre  JacquotJean-Pierre Jacquot
Jean-Pierre Jacquot
MRMiguel A. De la Rosa
Miguel A. De la Rosa
Jose Maria VegaJose Maria Vega
Jose Maria Vega